✦ LIBER ✦

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

✍ Scribed by Sullivan, G.J.; Rodriques-Torres, M.; Lawitz, E.; Poordad, F.; Kapoor, M.; Campbell, A.; Setze, C.; Xie, W.; Khatri, A.; Dumas, E.; Krishnan, P.; Pilot-Matias, T.; Williams, L.; Bernstein, B.

Book ID: 122555730
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 117 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(12)61222-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1187 ABT-450/RITONAVIR (ABT-450/R) COMBI

1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

✍ Lawitz, E.; Poordad, F.; DeJesus, E.; Kowdley, K.; Gaultier, I.; Cohen, D.; Xie, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 100 KB

1206 ABT-072 OR ABT-333 COMBINED WITH PE

1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

✍ Poordad, F.; Lawitz, E.; DeJesus, E.; Kowdley, K.V.; Gaultier, I.; Cohen, D.E.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

1220 ABT-450/RITONAVIR (ABT-450/R) COMBI

1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS

✍ Lawitz, E.; Gaultier, I.; Poordad, F.; Cohen, D.E.; Menon, R.; Larsen, L.M.; Pod 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 172 KB

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETIC

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

✍ Lalezari, J.; Poordad, F.; Mehra, P.; Nguyen, T.; Dejesus, E.; Godofsky, E.; Pat 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 54 KB

2009 SAFETY AND ANTIVIRAL ACTIVITY OF AN

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

✍ Lawitz, E.; Rodriquez-Torres, M.; Rustgi, V.K.; Hassanein, T.; Rahimy, M.H.; Cro 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

1186 SAFETY AND ANTIVIRAL ACTIVITY OF AB

1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS

✍ Lawitz, E.; Marbury, T.; Campbell, A.; Dumas, E.; Kapoor, M.; Pilot-Matias, T.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 118 KB